A new multisociety scientific statement outlines a 4-stage Female Life Stage framework for cardiovascular prevention in girls and women—perimenarche, ovarian cycling, perimenopause, and postmenopause—with pregnancy treated as a major risk-modifying event. Published as an American Heart Association-led guidance document with the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine, it aims to reduce missed CVD risk by aligning screening, prevention, and treatment across fragmented specialties.

Why It Matters To Your Practice

• NPs and PAs are often the first clinicians to spot the real-world overlap of hormonal, psychosocial, and cardiovascular risk—and this guidance reinforces that your frontline judgment is central, not secondary.

• The framework gives you a practical way to match CVD assessment to 4 clinically meaningful life stages instead of using a one-size-fits-all approach.

• It also flags pregnancy, including adverse pregnancy outcomes, as a key moment when future cardiovascular risk may first emerge or be unmasked.

Clinical Benefits

• You can use life stage to sharpen screening conversations around blood pressure, lipids, weight, diabetes risk, mental health, and reproductive history.

• The statement helps connect care across pediatrics, primary care, OB/GYN, cardiology, endocrinology, and maternal-fetal medicine—exactly the kind of coordination many NPs and PAs already lead.

• It supports earlier prevention in younger patients and more tailored risk reduction during perimenopause and postmenopause.

Managing Risks

• Watch for co-occurring dysregulation across hormonal, psychosocial, and cardiovascular domains, since these risks often travel together rather than in isolation.

• Document pregnancy history carefully, especially hypertensive disorders of pregnancy, gestational diabetes, and other adverse pregnancy outcomes that may signal higher long-term CVD risk.

• Because guidance has historically varied by specialty, use this crosswalked approach to reduce gaps in follow-up, counseling, and referral.

The Bottom Line

• This guidance gives NPs and PAs a stronger evidence-based framework to deliver stage-specific women’s cardiovascular care across the lifespan.

• Your role is pivotal: when you connect reproductive, mental, and cardiometabolic clues early, you are doing advanced prevention work that can change long-term outcomes.

• Bottom line: life stage is now part of good CVD care for girls and women, and frontline clinicians are the ones most likely to make it actionable.

Reference: Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine